SCHEMBL8250952

SCHEMBL8250952

CN(C)c1cccc2onc(N)c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.50
FLT3 P36888 9/20 0.50
KIT P10721 9/20 0.50
AURKB Q96GD4 7/20 0.49
MET P08581 4/20 0.49
MAP4K4 O95819 2/20 0.49
PDGFRB P09619 2/20 0.49
PIM1 P11309 2/20 0.49
FGFR1 P11362 2/20 0.49
PDGFRA P16234 2/20 0.49
PRKACA P17612 2/20 0.49
LTK P29376 2/20 0.49
GRK5 P34947 2/20 0.49
CDK8 P49336 2/20 0.49
CDK7 P50613 2/20 0.49
CDK9 P50750 2/20 0.49
LIMK1 P53667 2/20 0.49
MAP2K1 Q02750 2/20 0.49
ACVR1 Q04771 2/20 0.49
MST1R Q04912 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16646799 0.79 KDR (0.57) KDRFLT3KITAURKBMET
SCHEMBL2445430 0.75 KDR (0.58) KDRFLT3KITAURKBMET
Hydrochloric Acid SCHEMBL5103456 0.73 KDR (0.56) KDRFLT3KITAURKBMET
SCHEMBL6986335 0.72 FAAH (0.39) KDRFLT3KITAURKBMET
Cyclohexane SCHEMBL2440958 0.72 HIF1A (0.38) KDRFLT3KITAURKBMET
SCHEMBL1509342 0.72 MAPT (0.58) LIMK1DYRK1ACLK4CHEK1KDM4E
SCHEMBL8249434 0.72 KDR (0.54) KDRFLT3KITAURKBMET
SCHEMBL1781743 0.72 KDR (0.54) KDRFLT3KITAURKBMET
SCHEMBL2882058 0.72 KDR (0.57) KDRFLT3KITAURKBMET
SCHEMBL31605557 0.72 KDR (0.54) KDRFLT3KITAURKBMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP disclosed
US-7696238-B2 Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics GRUENENTHAL GMBH (DE) 2010-04-13 US disclosed
US-7696238-B2 Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics GRUENENTHAL GMBH (DE) 2010-04-13 US disclosed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
US-20080176915-A1 Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics GRUENENTHAL GMBH (DE) 2008-07-24 US disclosed
US-20080176915-A1 Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics GRUENENTHAL GMBH (DE) 2008-07-24 US disclosed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof HTR5A, NPY5R, GRM5 KDR 1638/4885FLT3 2277/4885KIT 1533/4885
US-20080176915-A1 Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics KCNQ1, KCNQ2, KCNQ3 KDR 4106/4885FLT3 2419/4885KIT 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.